123 related articles for article (PubMed ID: 37925340)
1. The impact of diabetes mellitus on hematopoietic stem cell mobilization, a-single center cohort study.
Çelik S; Kaynar L; Güven ZT; Begendi NK; Demir F; Keklik M; Ünal A
Transfus Apher Sci; 2023 Dec; 62(6):103838. PubMed ID: 37925340
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus as a poor mobilizer condition.
Fadini GP; DiPersio JF
Blood Rev; 2018 May; 32(3):184-191. PubMed ID: 29132746
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies.
Szmigielska-Kaplon A; Szemraj J; Hamara K; Robak M; Wolska A; Pluta A; Czemerska M; Krawczynska A; Jamroziak K; Szmigielska K; Robak T; Wierzbowska A
Biol Blood Marrow Transplant; 2014 Jul; 20(7):986-91. PubMed ID: 24680978
[TBL] [Abstract][Full Text] [Related]
5. Predictors of unsuccessful mobilization with granulocyte colony-stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation.
Chow S; Lazo-Langner A; Ormond G; Howson-Jan K; Xenocostas A
J Clin Apher; 2013 Aug; 28(4):285-92. PubMed ID: 23426584
[TBL] [Abstract][Full Text] [Related]
6. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
7. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
8. Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant.
Jaime-Pérez JC; Gómez-Galaviz AC; Turrubiates-Hernández GA; Picón-Galindo E; Salazar-Riojas R; Méndez-Ramírez N; Gómez-Almaguer D
Cytotherapy; 2020 Mar; 22(3):144-148. PubMed ID: 32057615
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
10. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
11. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
13. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.
Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A
Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941
[TBL] [Abstract][Full Text] [Related]
14. Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience.
Uzoka C; Liu LC; Park Y; Lin Y; Patel P; Campbell-Lee S; Sweiss K; Wang X; Tepak E; Peace D; Saraf S; Rondelli D; Mahmud N
J Clin Apher; 2021 Aug; 36(4):634-644. PubMed ID: 34046928
[TBL] [Abstract][Full Text] [Related]
15. Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma.
Bogucka-Fedorczuk A; Czyz A; Kalicińska E; Sawicki M; Laszkowska-Lewko M; Wicherska-Pawłowska K; Rybka J; Szeremet A; Prajs I; Szymczak D; Wróbel T
J Clin Apher; 2020 Aug; 35(4):246-254. PubMed ID: 32298020
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
17. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
[TBL] [Abstract][Full Text] [Related]
18. [Application of Mecapegfilgrastim for Peripheral Blood Hematopoietic Stem Cell Mobilization in Patients With Hematologic Neoplasms and Analysis of Predictors for Poor Mobilization].
Wen JJ; Shi L; Xu F; Zhou QL; Liu YP; Su J; Zhang Y; Qu W; Yue J; Liang XG; Hu H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):625-630. PubMed ID: 37248595
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
20. Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.
Kang KW; Lee SJ; Kim JH; Lee BH; Kim SJ; Park Y; Kim BS
BMC Cancer; 2020 Jul; 20(1):619. PubMed ID: 32615949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
